Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages

Expert Opinion on Drug Delivery

Volumn 12, Issue 6, 2015, Pages 1009-1026

  Lee, Wing Hin ^a   Loo, Ching Yee ^a   Traini, Daniela ^a   Young, Paul M ^a  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Liposome; Lung; Macrophage; Microparticle; Nanotechnology

Indexed keywords

CHITOSAN; CIPROFLOXACIN; CLATHRIN; CYCLODEXTRIN; DENDRIMER; DEXAMETHASONE; ECONAZOLE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; GELATIN; HYALURONIC ACID; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; LIPOSOME; MOXIFLOXACIN; NANOCARRIER; NANOPARTICLE; OFLOXACIN; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RIFAMPICIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANCER THERAPY; CAVEOLA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; GEOMETRY; HUMAN; INTERNALIZATION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MACROPHAGE ACTIVATION; MICROTECHNOLOGY; NANOTECHNOLOGY; NANOTOXICOLOGY; NEBULIZATION; NEOPLASM; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PNEUMONIA; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SURFACE CHARGE; TUBERCULOSIS; ANIMAL; CHEMISTRY; LUNG; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DENDRIMERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG; MACROPHAGES, ALVEOLAR; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYMERS;

EID: 84929759496     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1039509     Document Type: Review

References (132)

1. Volkman A, Gowans JL. The origin of macrophages from bone marrow in the rat. Br J Exp Pathol 1965;46:62-70
2. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-61
3. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007;317:666-70
4. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612-16
5. Auffray C, Sieweke MH, Geissmann F. Blood Monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669-92
6. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64
7. Biswas S, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-96
8. Schmid M, Varner J. Myeloid cells in tumor inflammation. Vasc Cell 2012;4:14
9. Gordon S, Martinez F. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604
10. Karp C, Murray P. Non-canonical alternatives: what a macrophage is 4. J Exp Med 2012;209:427-31
11. Tran T-H, Amiji MM. Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opin Drug Deliv 2015;12:393-414
12. Block ML, Hong J-S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98
13. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64
14. Mahor S, Dash BC, OConnor S, et al. Mannosylated polyethyleneiminehyaluronan nanohybrids for targeted gene delivery to macrophage-like cell lines. Bioconjug Chem 2012;23:1138-48
15. Park JH, Jin HE, Kim DD, et al. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm 2013;441:562-9
16. Chakravarthy KV, Davidson BA, Helinski JD, et al. Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine 2011;7:88-96
17. Hwang SM, Kim DD, Chung SJ, et al. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release 2008;129:100-6
18. Lauzon-Joset JF, Marsolais D, Langlois A, et al. Dysregulation of alveolar macrophages unleashes dendritic cell-mediated mechanisms of allergic airway inflammation. Mucosal Immunol 2014;7:155-64
19. Almatroodi SA, McDonald CF, Pouniotis DS. Alveolar macrophage polarisation in lung cancer. Lung Cancer Int 2014;2014:9
20. Furuie H, Yamasaki H, Suga M, et al. Altered accessory cell function of alveolar macrophages: A possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997;10:787-94
21. Khan S, Rahman HNA, Okamoto T, et al. Promotion of atherosclerosis by Helicobacter cinaedi infection that involves macrophage-driven proinflammatory responses. Sci Rep-Uk 2014;4:4680
22. Jayachandran R, BoseDasgupta S, Pieters J. Surviving the macrophage: tools and tricks employed by Mycobacterium tuberculosis. Curr Top Microbiol Immunol 2014;374:189-209
23. Rodriguez NE, Gaur U, Allen LAH, et al. Macrophage cholesterol mediates the entry, phagosome maturation, and intracellular survival of Leishmania chagasi parasites in a stage-specific and virulence-dependent manner. Am J Trop Med Hyg 2009;81:189
24. Ritchey JW, Tompkins WAF, Tompkins MB. Susceptibility to toxoplasma-gondii in Fiv-infected cats correlates with alveolar macrophage dysfunction. Faseb J 1995;9:A492
25. Poussin MA, Leitges M, Goldfine H. The ability of Listeria monocytogenes PIPLC to facilitate escape from the macrophage phagosome is dependent on host PKC beta. Microb Pathog 2009;46:1-5
26. Ahsan FL, Rivas IP, Khan MA, et al. Targeting to macrophages: role of physicochemical properties of particulate carriers -liposomes and microspheres -on the phagocytosis by macrophages. J Control Release 2002;79:29-40
27. Chono S, Tanino T, Seki T, et al. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 2006;14:557-66
28. Chono S, Tanino T, Seki T, et al. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm 2008;34:1090-6
29. Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010;54:1436-42
30. He CB, Hu YP, Yin LC, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010;31:3657-66
31. Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009;17:777-87
32. Zhu L, Chen L, Cao QR, et al. Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J Control Release 2011;152(Suppl 1):E190-E1
33. Karathanasis E, Ayyagari AL, Bhavane R, et al. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release 2005;103:159-75
34. Siekmeier R, Scheuch G. Treatment of systemic diseases by inhalation of biomolecule aerosols. J Physiol Pharmacol 2009;60:15-26
35. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules -principles, problems, and examples. J Physiol Pharmacol 2008;59:53-79
36. Hussain A, Arnold JJ, Khan MA, et al. Absorption enhancers in pulmonary protein delivery. J Control Release 2004;94:15-24
37. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014;75:81-91
38. Olsson B, Bondesson E, Borgström L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, editors. Controlled pulmonary drug delivery. Springer; New York: 2011. p. 21-50
39. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers -therapeutic possibilities and technological challenges. Lancet Respir Med 2013;1:402-13
40. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70
41. Fels AOS, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986;60:353-69
42. Kunjachan S, Jose S, Thomas CA, et al. Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy. Fundam Clin Pharmacol 2012;26:63-71
43. Vyas SP, Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin Drug Deliv 2007;4:95-9
44. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax 2014;69:811-18
45. Bai FF, Ni B, Liu MJ, et al. Mycoplasma hyopneumoniae-derived lipid-Associated membrane proteins induce apoptosis in porcine alveolar macrophage via increasing nitric oxide production, oxidative stress, and caspase-3 activation. Vet Immunol Immunopathol 2013;155:155-61
46. Dubourdeau M, Athman R, Balloy V, et al. Interaction of Aspergillus fumigatus with the alveolar macrophage. Med Mycol 2006;44:S213-S7
47. Gangadhar KN, Adhikari K, Srichana T. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Int J Pharm 2014;471:430-8
48. Marriott HM, Whyte MK, Dockrell DH. Macrophage apoptosis after influenza A virus infection. Am J Resp Crit Care Med 2009;179:A5168
49. Mehrotra P, Jamwal SV, Saquib NM, et al. Pathogenicity of Mycobacterium tuberculosis is expressed by regulating metabolic thresholds of the host macrophage. Plos Pathog 2014;10:e1004265
50. Cambier CJ, Takaki KK, Larson RP, et al. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 2014;505:218-22
51. Jain S, Amiji M. Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system. Biomacromolecules 2012;13:1074-85
52. Bhardwaj A, Kumar L, Narang RK, et al. Development and characterization of ligand-Appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cell Nanomed Biotechnol 2013;41:52-9
53. Barros NB, Migliaccio V, Facundo VA, et al. Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: Macrophage as target cell. Exp Parasitol 2013;135:337-43
54. Gao JM, Chen PM, Singh Y, et al. Novel Monodisperse PEGtide Dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting. Bioconjugate Chem 2013;24:1332-44
55. Wen ZS, Liu LJ, Qu YL, et al. Chitosan nanoparticles attenuate hydrogen peroxide-induced stress injury in mouse macrophage RAW264.7 cells. Mar Drugs 2013;11:3582-600
56. Asthana GS, Asthana A, Kohli DV, et al. Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting. Biomed Res Int 2014
57. Makino K, Yamamoto N, Higuchi K, et al. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf B 2003;27:33-9
58. Maretti E, Rossi T, Bondi M, et al. Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis. Int J Pharm 2014;462:74-82
59. Riou A, Chauveau F, Cho TH, et al. MRI assessment of the intra-carotid route for macrophage delivery after transient cerebral ischemia. Nmr Biomed 2013;26:115-23
60. dAngelo I, Conte C, La Rotonda MI, et al. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev 2014;75:92-111
61. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145:182-95
62. Geiser M. Update on macrophage clearance of inhaled micro-And nanoparticles. J Aerosol Med Pulm Drug Deliv 2010;23:207-17
63. Todoroff J, Vanbever R. Fate of nanomedicines in the lungs. Curr Opin Colloid Interface Sci 2011;16:246-54
64. Hillaireau H, Couvreur P. Nanocarriers entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96
65. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999;17:593-623
66. Xie SY, Tao YF, Pan YH, et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release 2014;187:101-17
67. Yacobi NR, Malmstadt N, Fazlollahi F, et al. Mechanisms of alveolar epithelial translocation of a defined population of nanoparticles. Am J Respir Cell Mol Biol 2010;42:604-14
68. Fresta M, Spadaro A, Cerniglia G, et al. Intracellular accumulation of ofloxacinloaded liposomes in human synovial fibroblasts. Antimicrob Agents Chemother 1995;39:1372-5
69. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31-9
70. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003;3:571-81
71. Rejman J, Conese M, Hoekstra D. Gene transfer by means of lipo-And polyplexes: Role of clathrin and caveolaemediated endocytosis. J Liposome Res 2006;16:237-47
72. Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annu Rev Biochem 2009;78:857-902
73. Hirota K, Hasegawa T, Hinata H, et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release 2007;119:69-76
74. Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm 2015;89:163-74
75. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 2008;25:1815-21
76. Epstein-Barash H, Gutman D, Markovsky E, et al. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release 2010;146:182-95
77. Pricer WE, Ashwell G. The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem 1971;246:4825-33
78. Tabata Y, Ikada Y. Effect of the size and surface-charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988;9:356-62
79. Gallagher JE, George G, Brody AR. Sialic-Acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage Membranes. Am Rev Respir Dis 1987;135:1345-52
80. Fontana G, Licciardi M, Mansueto S, et al. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001;22:2857-65
81. Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposomeencapsulated antibiotics for therapy of intracellular Mycobacterium-Avium infection. Antimicrob Agents Chemother 1995;39:2104-11
82. Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. Plos One 2010;5
83. Sharma G, Valenta DT, Altman Y, et al. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 2010;147:408-12
84. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006;103:4930-4
85. Onoshita T, Shimizu Y, Yamaya N, et al. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf B Biointerfaces 2010;76:151-7
86. Brandhonneur N, Chevanne F, Vie V, et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009;36:474-85
87. Kunjachan S, Gupta S, Dwivedi AK, et al. Chitosan-based macrophagemediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul 2011;28:301-10
88. Hirota K, Hasegawa T, Nakajima T, et al. Phagostimulatory effect of uptake of PLGA microspheres loaded with rifampicin on alveolar macrophages. Colloids Surf B Biointerfaces 2011;87:293-8
89. Hasegawa T, Hirota K, Tomoda K, et al. Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent. Colloids Surf B Biointerfaces 2007;60:221-8
90. Hasegawa T, Iijima K, Hirota K, et al. Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those attached to the macrophage membrane. Colloids Surf B Biointerfaces 2008;63:209-16
91. Makino K, Nakajima T, Shikamura M, et al. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf B Biointerfaces 2004;36:35-42
92. Tomoda K, Kojima S, Kajimoto M, et al. Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2005;45:1-6
93. Tomoda K, Makino K. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2007;55:115-24
94. Hirota K, Hasegawa T, Nakajima T, et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release 2010;142:339-46
95. Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971;134:713-40
96. Yang Y, Bajaj N, Xu P, et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009;30:1947-53
97. Hirota K, Kawamoto T, Nakajima T, et al. Distribution and deposition of respirable PLGA microspheres in lung alveoli. Colloids Surf B Biointerfaces 2013;105:92-7
98. Verma RK, Kaur J, Kumar K, et al. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008;52:3195-201
99. Yoshida A, Matumoto M, Hshizume H, et al. Selective delivery of rifampicin incorporated into poly (DL-lactic-coglycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin. Microbes Infect 2006;8:2484-91
100. Tiwari S, Chaturvedi AP, Tripathi YB, et al. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSciTech 2011;12:900-8
101. Parikh R, Dalwadi S, Aboti P, et al. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis. J Antibiot 2014;67:387-94
102. Zhou H, Zhang Y, Biggs DL, et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Release 2005;107:288-99
103. Sharma R, Yadav AB, Muttil P, et al. Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis 2011;91:107-10
104. Tiwari S, Chaturvedi AP, Tripathi YB, et al. Microspheres based on mannosylated lysine-co-sodium alginate for macrophage-specific delivery of isoniazid. Carbohyd Polym 2012;87:1575-82
105. Wang C, Hickey AJ. Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency. Int J Pharm 2010;396:99-104
106. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48
107. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49-60
108. Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269:37-49
109. Chono S, Kaneko K, Yamamoto E, et al. Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug Dev Ind Pharm 2010;36:102-7
110. Vyas SP, Quraishi S, Gupta S, et al. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296:12-25
111. Chono S, Tanino T, Seki T, et al. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008;127:50-8
112. Chono S, Tanino T, Seki T, et al. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 2007;59:75-80
113. Wijagkanalan W, Kawakami S, Takenaga M, et al. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release 2008;125:121-30
114. Changsan N, Nilkaeo A, Pungrassami P, et al. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target 2009;17:751-62
115. Vyas SP, Khatri K, Goyal AK. Functionalized nanocarrier(s) to image and target fungi infected immune cells. Med Mycol 2009;47:S362-S8
116. Vyas SP, Katare YK, Mishra V, et al. Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm 2000;210:1-14
117. Chuealee R, Aramwit P, Noipha K, et al. Bioactivity and toxicity studies of amphotericin B incorporated in liquid crystals. Eur J Pharm Sci 2011;43:308-17
118. Goldbach P, Dumont S, Kessler R, et al. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Am J Physiol Lung Cell Mol Physiol 1996;270:L429-L34
119. Phillips NC, Moras ML, Chedid L, et al. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 1985;45:128-34
120. Eisenberg BL, Taylor DD, Weese JL. Aerosolized gamma-interferon and lipopolysaccharide enhances cytotoxicity of murine pulmonary alveolar macrophages. J Immunother 1991;10:51-6
121. Fidler IJ, Raz A, Fogler WE, et al. Design of liposomes to improve delivery of macrophage-Augmenting agents to alveolar macrophages. Cancer Res 1980;40:4460-6
122. Wijagkanalan W, Kawakami S, Higuchi Y, et al. Intratracheally instilled mannosylated cationic liposome/NF kappa B decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release 2011;149:42-50
123. Wijagkanalan W, Higuchi Y, Kawakami S, et al. Enhanced antiinflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol 2008;74:1183-92
124. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 2009;26:2588-98
125. Salem II, Duzgunes N. Efficacies of cyclodextrin-complexed and liposomeencapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int J Pharm 2003;250:403-14
126. Wada K, Arima H, Tsutsumi T, et al. Improvement of gene delivery mediated by mannosylated dendrimer/a-cyclodextrin conjugates. J Control Release 2005;104:397-413
127. Kumar PV, Asthana A, Dutta T, et al. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 2006;14:546-56
128. Mullaicharam AR, Murthy RSR. Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat. J Drug Deliv Sci Tec 2004;14:99-104
129. Akbari V, Abedi D, Pardakhty A, et al. Ciprofloxacin nano-niosomes for targeting intracellular infections: An in vitro evaluation. J Nanopart Res 2013;15:1-14
130. Russell DG, Barry CE, Flynn JL. Tuberculosis: what we dont know can, and does, hurt us. Science 2010;328:852-6
131. Tartaj P, Morales MP, Veintemillas-Verdaguer S, et al. Synthesis, properties and biomedical applications of magnetic nanoparticles. Elsevier; Amsterdam, The Netherlands: 2006
132. Saraogi GK, Gupta P, Gupta UD, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010;385:143-9